Page 14 - மார்பக புற்றுநோய் ஆராய்ச்சி அடித்தளம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi view more  Credit: Ludwig Cancer Research FEBRUARY 15, 2021, NEW YORK - A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors. The tumors in question are relatively less reliant on burning sugar through a biochemical process known as glycolysis. Researchers led by Taha Merghoub and Jedd Wolchok of the Ludwig Center at Memorial Sloan Kettering Cancer Center (MSK) and former postdoc Roberta Zappasodi now at Weill Cornell Medicine have discovered that in a mouse model of glycolysis-deficient tumors, CTLA-4 blockade does much more than stimulate cancer-targeting T cells of the immune system. In such tumors, anti-CTLA-4 therapy also destabilizes and reprograms regulatory T

United statesTaha merghoubRoberta zappasodiBreast cancer research foundationUs national cancer instituteWeill cornell medical collegeA ludwig cancer researchLudwig cancer researchLudwig centerLudwig collaborative swim across america laboratorySwiss national science foundationParker institute for cancer immunotherapyEuropean research councilJedd wolchokMemorial sloan kettering cancer centerRoberta zappasodi now